Summary of Study ST001618

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR001038. The data can be accessed directly via it's Project DOI: 10.21228/M8HX30 This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Show all samples  |  Perform analysis on untargeted data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001618
Study TitleMetabolomics Analysis: Opioid Addiction Project (Golestan Cohort Study) - MS (part-I)
Study TypeUntargeted LC-MS Metabolomics Study
Study SummaryDrug addiction is a major threat to the public health in the US and many other countries. Opioid abuse is associated with increased risks for cancer, psychological complications, heart and lung disease, and infections of the liver and blood. Because metabolites are intrinsically involved in multiple metabolic pathways in vivo, the relative quantification of metabolites in body fluids (for example urine) can provide a profile of the metabolic state of an organism. Metabolomics is a powerful technique for revealing the impact of exposure on the overall biochemistry of an individual or system. Opioids can modify the output of urinary metabolites through many integrated neural and hormonal mechanisms within the periphery, central nervous system, and kidneys. Opioids modulate the expression of genes involved in neuroplasticity through epigenetic and possibly RNA modifications, ultimately change the intracellular signaling cascades and dysfunction, and cause long-lasting changes in metabolome. The objective of this study is to identify how opium impacts metabolic pathways to provide markers of abuse, long-term opium addiction, the addiction molecular pathway, and unknown metabolites that are important to differentiation of the study phenotypes. To reach these goals in the present study, the urine specimens of opium abusers and non-users as controls will be profiled using an untargeted liquid chromatography mass spectrometric (LC-MS/MS) at University of North Carolina at Chapel Hill. The Golestan Cohort Study is conducted in Northeast of Iran to primarily study the risk factors for upper gastrointestinal cancers in this high-risk region, in which about 50,000 volunteers were analyzed for opium users and their mortality. More than 8,000 of participants (17%) age 40-75 reported opium use with a mean duration of 12.7 years. Opium was either smoked or orally consumed. The participants were selected from the cohort stratified by opium use patterns and tobacco use.
Institute
University of North Carolina at Chapel Hill
DepartmentNutrition
Last NameSumner
First NameSusan
Address500 Laureate Way, Kannapolis, NC 28081
Emailsusan_sumner@unc.edu
Phone919-541-4456
Submit Date2020-12-01
Num Groups2
Total Subjects298
Raw Data AvailableYes
Raw Data File Type(s)raw(Thermo)
Analysis Type DetailLC-MS
Release Date2022-05-02
Release Version1
Susan Sumner Susan Sumner
https://dx.doi.org/10.21228/M8HX30
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:

Project:

Project ID:PR001038
Project DOI:doi: 10.21228/M8HX30
Project Title:Metabolomics Analysis: Opioid Addiction Project
Project Summary:Drug addiction is a major threat to the public health in the US and many other countries. Opioid abuse is associated with increased risks for cancer, psychological complications, heart and lung disease, and infections of the liver and blood. Because metabolites are intrinsically involved in multiple metabolic pathways in vivo, the relative quantification of metabolites in body fluids (for example urine) can provide a profile of the metabolic state of an organism. Metabolomics is a powerful technique for revealing the impact of exposure on the overall biochemistry of an individual or system. Opioids can modify the output of urinary metabolites through many integrated neural and hormonal mechanisms within the periphery, central nervous system, and kidneys. Opioids modulate the expression of genes involved in neuroplasticity through epigenetic and possibly RNA modifications, ultimately change the intracellular signaling cascades and dysfunction, and cause long-lasting changes in metabolome. The objective of this study is to identify how opium impacts metabolic pathways to provide markers of abuse, long-term opium addiction, the addiction molecular pathway, and unknown metabolites that are important to differentiation of the study phenotypes. To reach these goals in the present study, the urine specimens of opium abusers and non-users as controls was profiled using an untargeted nuclear magnetic resonance spectroscopy (NMR) metabolomics, and a quantitative targeted liquid chromatography mass spectrometric (LC-MS/MS) at University of North Carolina at Chapel Hill. The Golestan Cohort Study is conducted in Northeast of Iran to primarily study the risk factors for upper gastrointestinal cancers in this high-risk region, in which about 50,000 volunteers were analyzed for opium users and their mortality. More than 8,000 of participants (17%) age 40-75 reported opium use with a mean duration of 12.7 years. Opium was either smoked or orally consumed. The participants were selected from the cohort stratified by opium use patterns and tobacco use.
Institute:University of North Carolina at Chapel Hill
Laboratory:UNC-NRI Sumner Lab
Last Name:Sumner
First Name:Susan
Address:500 Laureate Way, Kannapolis, NC, 28081, USA
Email:susan_sumner@unc.edu
Phone:919-622-4456
Publications:1. Untargeted Metabolomics: Biochemical Perturbations in Golestan Cohort Study Opium Users Inform Intervention Strategies: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783045/
2. Metabolomics reveals biomarkers of opioid use disorder: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862627/

Subject:

Subject ID:SU001695
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Age Or Age Range:40-75
Gender:Male and female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Phenotype
SA137238U_175Non-User
SA137239U_203Non-User
SA137240U_204Non-User
SA137241U_17Non-User
SA137242U_168Non-User
SA137243U_166Non-User
SA137244U_167Non-User
SA137245U_21Non-User
SA137246U_169Non-User
SA137247U_211Non-User
SA137248U_230Non-User
SA137249U_234Non-User
SA137250U_235Non-User
SA137251U_228Non-User
SA137252U_221Non-User
SA137253U_165Non-User
SA137254U_217Non-User
SA137255U_220Non-User
SA137256U_210Non-User
SA137257U_156Non-User
SA137258U_130Non-User
SA137259U_131Non-User
SA137260U_132Non-User
SA137261U_13Non-User
SA137262U_113Non-User
SA137263U_101Non-User
SA137264U_103Non-User
SA137265U_106Non-User
SA137266U_138Non-User
SA137267U_14Non-User
SA137268U_152Non-User
SA137269U_153Non-User
SA137270U_239Non-User
SA137271U_151Non-User
SA137272U_147Non-User
SA137273U_140Non-User
SA137274U_145Non-User
SA137275U_146Non-User
SA137276U_16Non-User
SA137277U_257Non-User
SA137278U_64Non-User
SA137279U_71Non-User
SA137280U_8Non-User
SA137281U_62Non-User
SA137282U_59Non-User
SA137283U_45Non-User
SA137284U_51Non-User
SA137285U_57Non-User
SA137286U_80Non-User
SA137287U_83Non-User
SA137288U_89Non-User
SA137289U_93Non-User
SA137290U_94Non-User
SA137291U_88Non-User
SA137292U_87Non-User
SA137293U_84Non-User
SA137294U_85Non-User
SA137295U_86Non-User
SA137296U_43Non-User
SA137297U_39Non-User
SA137298U_282Non-User
SA137299U_285Non-User
SA137300U_295Non-User
SA137301U_279Non-User
SA137302U_278Non-User
SA137303U_10Non-User
SA137304U_268Non-User
SA137305U_273Non-User
SA137306U_296Non-User
SA137307U_304Non-User
SA137308U_318Non-User
SA137309U_324Non-User
SA137310U_325Non-User
SA137311U_316Non-User
SA137312U_314Non-User
SA137313U_309Non-User
SA137314U_310Non-User
SA137315U_311Non-User
SA137316U_25Non-User
SA137317U_293Non-User
SA137318SP_27Study_Pools
SA137319SP_28Study_Pools
SA137320SP_29Study_Pools
SA137321SP_26Study_Pools
SA137322SP_25Study_Pools
SA137323SP_23_2Study_Pools
SA137324SP_23_3Study_Pools
SA137325SP_24Study_Pools
SA137326SP_30Study_Pools
SA137327SP_31Study_Pools
SA137328SP_7Study_Pools
SA137329SP_8Study_Pools
SA137330SP_9Study_Pools
SA137331SP_6Study_Pools
SA137332SP_5Study_Pools
SA137333SP_32Study_Pools
SA137334SP_33Study_Pools
SA137335SP_4Study_Pools
SA137336SP_23_1Study_Pools
SA137337SP_3Study_Pools
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 336

Collection:

Collection ID:CO001688
Collection Summary:Non-fasted urine sample; spot urine.
Sample Type:Urine
Storage Conditions:-80℃

Treatment:

Treatment ID:TR001708
Treatment Summary:N/A

Sample Preparation:

Sampleprep ID:SP001701
Sampleprep Summary:Urine samples were allowed to thaw at 4 °C overnight. All samples were vortexed via multiple tube vortex for 2 min at 3000 rpm. The urine were spin downed using centrifuge at 1000 rpm for 30 sec. A volume of 7 µL aliquot of all 298 samples were transferred into one 10.0 mL tube labeled as pooled. A volume of 50 µL of urine (including study pool) was transferred to a new, pre-labeled Lo-Bind Eppendorf tube. A volume of 400 µL Protein Precipitation Buffer with Internal Standard (500 ng/ml Tryptophan-d5 in methanol) was added to each tube. All individual samples were thoroughly mixed on multiple tube vortexer for 2 mins at 5000 rpm. The protein precipitate was palleted using a centrifuge operating at room temperature and at 16,000 rcf for 4 min. A volume of 350 µl of the supernatant was transferred into pre-labeled 2.0 ml Low-bind Eppendorf tube. Sample were dried using speed vac overnight. A volume of 100 µL of reconstitution buffer (95:5 Water-Methanol) was added to each sample. Samples were thoroughly mixed on multiple tube vortexer for 10 mins at 5000 rpm. Samples were centrifuged at 4°C and at 16,000 rcf for 10 min. The supernatant was transferred to pre-labeled autosampler vials. A volume of 5 µL was injected onto column.
Processing Storage Conditions:On ice
Extract Storage:Described in summary

Combined analysis:

Analysis ID AN002653
Analysis type MS
Chromatography type Reversed phase
Chromatography system Thermo Scientific™ Vanquish™ UPHPLC
Column Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,3um)
MS Type ESI
MS instrument type Orbitrap
MS instrument name Thermo Q Exactive HF hybrid Orbitrap
Ion Mode POSITIVE
Units Peak area

Chromatography:

Chromatography ID:CH001957
Instrument Name:Thermo Scientific™ Vanquish™ UPHPLC
Column Name:Waters ACQUITY UPLC HSS T3 (100 x 2.1mm,3um)
Column Pressure:6000-10000
Column Temperature:50
Flow Gradient:Time(min) Flow Rate %A %B Curve 1. 0 0.4 99.0 1.0 5 2. 1.00 0.4 99.0 1.0 5 3. 16.00 0.4 1.0 99.0 5 4. 19.00 0.4 1.0 99.0 5 5. 19.50 0.4 99.0 1.0 5
Flow Rate:0.4 ml/min
Injection Temperature:8
Solvent A:100% water; 0.1% formic acid
Solvent B:100% methanol; 0.1% formic acid
Chromatography Type:Reversed phase

MS:

MS ID:MS002461
Analysis ID:AN002653
Instrument Name:Thermo Q Exactive HF hybrid Orbitrap
Instrument Type:Orbitrap
MS Type:ESI
MS Comments:Instrument: Thermo Q Exactive HFx Software: Progenesis QI 2.0
Ion Mode:POSITIVE
Capillary Temperature:275 °C
Capillary Voltage:3.5 KV
Collision Energy:10-35, ramp
Collision Gas:N2
Dry Gas Flow:45
Dry Gas Temp:325°C
Fragmentation Method:CID
Desolvation Gas Flow:45
  logo